Skip to main content

Luminex Q2 Revenues Climb 16 Percent, Loss Narrows

NEW YORK, July 28 (GenomeWeb News) - Luminex yesterday reported increased revenues and a narrowing loss for the second quarter of 2005.


Revenues for the quarter totaled $10.7 million, a 16 percent increase over last year's revenues of $9.2 million during the same quarter. Of total revenues, $4.4 million came from sales of Luminex instruments, $3.9 million from consumables, $1.2 million from royalties, and $1.1 million from other sources.


Research and development costs climbed to $1.5 million, up from $1 million during the year-ago quarter.


Luminex's net loss declined to $363,000, or $.01 per share, from $1.1 million, or $.04 per share, for last year's second quarter.


As of June 30, Luminex had $19.5 million in cash and cash equivalents, and $8.9 million in short-term investments.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.